Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Main Authors: Diallo, Aldiouma, Sow, Samba O., Idoko, Olubukola T., Hirve, Siddhivinayak, Findlow, Helen, Preziosi, Marie-Pierre, Elie, Cheryl, Kulkarni, Prasad S., Parulekar, Varsha, Diarra, Bou, Cheick Haidara, Fadima, Diallo, Fatoumata, Tapia, Milagritos, Akinsola, Adebayo K., Adegbola, Richard A., Bavdekar, Ashish, Juvekar, Sanjay, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, LaForce, Marc F., Plikaytis, Brian D., Enwere, Godwin C., Tang, Yuxiao, Borrow, Ray, Carlone, George, Viviani, Simonetta
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639491/
https://ncbi.nlm.nih.gov/pubmed/26553684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ518
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares